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ABSTRACT
Objective: To evaluate the feasibility of a phase 3
randomised controlled trial (RCT) of a website (Living
Well with Asthma) to support self-management.
Design and setting: Phase 2, parallel group, RCT,
participants recruited from 20 general practices across
Glasgow, UK. Randomisation through automated voice
response, after baseline data collection, to website
access for minimum 12 weeks or usual care.
Participants: Adults (age≥16 years) with physician
diagnosed, symptomatic asthma (Asthma Control
Questionnaire (ACQ) score ≥1). People with unstable
asthma or other lung disease were excluded.
Intervention: ‘Living Well with Asthma’ is a desktop/
laptop compatible interactive website designed with
input from asthma/ behaviour change specialists, and
adults with asthma. It aims to support optimal
medication management, promote use of action plans,
encourage attendance at asthma reviews and increase
physical activity.
Outcome measures: Primary outcomes were
recruitment/retention, website use, ACQ and mini-
Asthma Quality of Life Questionnaire (AQLQ).
Secondary outcomes included patient activation,
prescribing, adherence, spirometry, lung inflammation
and health service contacts after 12 weeks. Blinding
postrandomisation was not possible.
Results: Recruitment target met. 51 participants
randomised (25 intervention group). Age range
16–78 years; 75% female; 28% from most deprived
quintile. 45/51 (88%; 20 intervention group) followed
up. 19 (76% of the intervention group) used the
website, for a mean of 18 min (range 0–49). 17 went
beyond the 2 ‘core’ modules. Median number of logins
was 1 (IQR 1–2, range 0–7). No significant difference
in the prespecified primary efficacy measures of ACQ
scores (−0.36; 95% CI −0.96 to 0.23; p=0.225), and
mini-AQLQ scores (0.38; −0.13 to 0.89; p=0.136). No
adverse events.
Conclusions: Recruitment and retention confirmed
feasibility; trends to improved outcomes suggest use of
Living Well with Asthma may improve self-management
in adults with asthma and merits further development
followed by investigation in a phase 3 trial.
Trial registration number: ISRCTN78556552;
Results.
INTRODUCTION
Asthma is a common condition affecting
over 300 million people worldwide, with
increasing global prevalence.1 While there
are newer pharmacological treatments for
individuals with severe asthma,2–5 improve-
ments in outcomes for the majority with
mild-to-moderate asthma have stalled.6 A
recent UK review of asthma deaths showed
potentially avoidable factors in the majority,
particularly relating to self-management and
adherence to treatment.7
Despite clear evidence that self-
management education, asthma action plan
Strengths and limitations of this study
▪ A recent UK review of asthma deaths showed
many could have been avoided if medication
management and other self-management strat-
egies had been better, so finding optimum
approaches to support self-management of
asthma is critical and digital interventions show
promise.
▪ The ‘Living Well with Asthma’ website was itera-
tively designed with input from experts in
asthma, self-management support, behaviour
change and adults with asthma themselves; it
aims to support optimal medication manage-
ment, promote use of action plans, encourage
attendance at asthma reviews and increase phys-
ical activity.
▪ We conducted a phase 2 parallel group, rando-
mised controlled trial; randomisation was
through automated voice response, after baseline
data collection but blinding of the researchers or
participants at outcome, measurement was not
possible.
▪ Our low response rate is a concern; however, we
have described our population in detail (unlike
previous reports of digital interventions for
asthma self-management), and our baseline
characteristics demonstrate that patients were
recruited from a range of socioeconomic
backgrounds.
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use and regular professional review improve outcomes,8
translation into everyday practice has proven difﬁcult,6
and most patients still lack an action plan and sufﬁcient
understanding to self-manage effectively. Poor adher-
ence to regular preventative medication (primarily with
inhaled corticosteroids, ICS) is a particular problem.
Using digital interventions to promote self-management
behaviours shows promise, but uncertainty persists as to
the most effective formulation of the intervention and
the target population.9
In this phase 2, pilot randomised controlled trial
(RCT), we evaluated the feasibility and effectiveness of
using a low-intensity online intervention aimed at pro-
moting effective self-management (especially adherence
to ICS) in adults with mild-to-moderate asthma, com-
pared with usual care. We developed the intervention
(‘Living Well with Asthma’) incorporating evidence
from the literature and relevant theory. Several phases of
user testing in alignment with the ‘person-based
approach’ to developing digital behaviour change inter-
ventions were undertaken.10 Following the Medical
Research Council (MRC) guidance on developing and
evaluating complex interventions,11 our objective was to
determine the feasibility of conducting a phase 3 RCT,
and obtained initial estimates of effects on outcomes.
METHODS
Our trial protocol is described in detail elsewhere.12
A brief summary is provided here.
Settings and participants
We recruited from 20 general practices in Glasgow, UK,
between 23/09/2013 and 21/02/2014, using clinical
databases to identify potential participants who were
invited by mail to participate and complete the Asthma
Control Questionnaire (ACQ). We recruited adults aged
16 years or older, with a physician diagnosis of asthma
and ACQ score ≥1, who provided written informed
consent. For full inclusion and exclusion criteria see
box 1. Our search strategy is shown in the online supple-
mentary data ﬁle.
Study design overview and intervention description
We conducted a non-blinded pilot RCT of access to the
‘Living Well with Asthma’ website versus usual care for
51 participants. Participants were assessed in their own
homes at baseline and at 12 weeks or as soon as possible
after this date.
The intervention development is described else-
where,13 but in summary aimed to (1) provide under-
standing of current level of asthma control and how to
improve it, speciﬁcally by optimising use of prescribed
medication; (2) challenge attitudes and concerns
around medications; (3) learn how to get the most out
of their annual asthma review; (4) prompt provision and
use of a personal asthma action plan from a health pro-
fessional and (5) send timely reminders for inﬂuenza
vaccination and reordering reﬁll inhaler prescriptions.
The website did not advise medication changes, but sug-
gested contacting a health professional if inadequate
control was identiﬁed, with clear advice for seeking help
in an emergency. The website is interactive, aiming to
engage the user in recognising that their asthma is
uncontrolled, and illustrate the beneﬁts via case vign-
ettes (based on real life examples) of taking their medi-
cations as prescribed. The website is tailored based on
their current use of preventer inhalers (never been pre-
scribed; prescribed but do not really use; use regularly).
There is a ‘4-week challenge’ that users can sign up to,
where they commit to taking their preventer regularly
for 4 weeks, are guided through establishing their per-
sonal barriers to regular use (see screenshot in online
supplementary data ﬁle for further illustration) and
developing potential solutions to these barriers.
The intervention group was given website login details
and a computer link, and advised to use the website as
much or as little as they wished (total time to visit all
pages once ∼90 min). We developed the website using
an open source software package called LifeGuide.14 15
Randomisation and blinding
Randomisation occurred after baseline data collection,
using a third party interactive voice response system
(IVRS) ensuring allocation concealment. The random-
isation schedule was generated in advance of the
study by the Robertson Centre for Biostatistics, in a 1:1
ratio, using the method of randomised permuted
blocks of length 4, without stratiﬁcation. Access to the
Box 1 Inclusion and exclusion criteria
Inclusion criteria
▸ Written informed consent
▸ Age 16 years or older
▸ Diagnosis of asthma by a health professional, and duration of
asthma symptoms >1 year
▸ Asthma Control Questionnaire score (ACQ; six-questions
version) ≥1 suggesting poorly controlled asthma
▸ Ability to access the internet via desktop or laptop (tablets and
smartphones not sufficient)
Exclusion criteria
▸ Unstable asthma as defined as the presence of one or more of
the following events in the 4 weeks prior to randomisation:
– Asthma-related hospital admission
– Emergency department attendance for asthma
– ‘Out of hours’ visit of patients to the general practitioner
(GP) for asthma
– GP visit to patient at home for asthma
▸ Presence of active lung disease other than asthma
▸ Mental impairment or language difficulties that make informed
consent impossible
▸ Frequent asthma exacerbations with >4 courses of oral pred-
nisolone in the 12 months prior to randomisation
▸ Cognitive impairment
▸ Terminal illness
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randomisation schedule was restricted to those within
the Centre with responsibility for provision of the IVRS.
The comparison group was offered access to the inter-
vention after the follow-up visit.
Primary outcomes
The primary end points were: recruitment and retention
rates at follow-up, website use, and changes from baseline
for ACQ16 and mini-Asthma Quality of Life
Questionnaire (AQLQ) scores.17 The ACQ and
mini-AQLQ have a minimal clinically important differ-
ence (MCID) of 0.5.18 This pilot study was not powered
to detect a difference in these two clinical outcomes; they
were included in order to assess feasibility and inform
sample size calculations for a future full-scale RCT.
Secondary outcomes
We evaluated a range of secondary outcomes in order to
assess their feasibility for use in a future full-scale RCT.
Individual domains of the mini-AQLQ were reported.
These comprise of symptoms, activity limitation, emo-
tional function and environmental stimuli. Knowledge,
skills and conﬁdence to manage health was measured
via the Patient Activation Measure (PAM).19
Self-reported adherence was assessed by both enquiring
what proportion of prescribed ICS were actually taken,
and via the Morisky Medication Adherence Scale
(MMAS).20 Airway inﬂammation is measured by fraction
exhaled nitric oxide (FeNO).21 Lung function was
assessed via prebronchodilator spirometry, including
forced expiratory volume in 1 s (FEV1); FEV1 percentage
predicted; and FEV1/forced vital capacity. Lung function
(spirometry) was performed to the American Thoracic
Society (ATS) standards,21 22 where possible, and the
proportion of tests not meeting these standards
recorded. As well as the asthma-speciﬁc mini-AQLQ,
generic quality of life was measured using the EuroQol
(EQ)-5D.23 We collected changes to medication use,
recorded numbers of health service contacts and severe
exacerbations were noted by recording the number of
oral prednisolone courses. These data were self-
reported. Those in the intervention group received the
problematic experience of therapies scale (PETS) to
facilitate understandings of barriers to using the website,
and following its advice.
Data analysis
Continuous data are summarised as mean and SD or
range, or as median and IQR, and categorical data as
counts and percentages. Linear regression was used to
estimate differences in continuous outcomes between
groups at follow-up, adjusting for baseline scores.
Estimated between-group differences are reported with a
95% CI and p value. For continuous outcomes that were
not normally distributed, changes from baseline were
compared between groups using Wilcoxon rank-sum
tests. Categorical variables were compared between
groups using Fisher’s exact test. All analyses were carried
out using SPSS Statistics V.22 and Microsoft Ofﬁce Excel.
The primary analysis was intention-to-treat and involved
all patients who were randomly assigned, except with
spirometry where only those meeting ATS/European
Respiratory Society (ERS) eligibility criteria will be
analysed.22
RESULTS
Baseline characteristics
The groups were largely well matched. Participants were
aged between 16 and 78 years, and 75% were female
(table 1).
Primary outcomes
Recruitment and retention)
Recruitment target of 50 participants was met (ﬁgure 1).
Participating practices were mostly urban, and spread
across deprivation categories. Response rate to the postal
invitation was 4.6%, lower than anticipated, and only
27% of those screened were subsequently randomised,
with the majority failing due to ACQ<1 (75%). Those
randomised were younger (45.5 vs 51.5 years) and more
likely to be female (75% vs 50%) than screen failures,
but with similar socioeconomic deprivation. The attri-
tion rate (not completing follow-up) was 12%: 20% in
the intervention group, 4% in the comparison group
(Fisher’s test p=0.10).
Website use
Nineteen of the 25 participants in the intervention
group logged in at least once (76%) with 17 going
beyond the initial ‘core’ section. The subsequent section
was tailored depending on which of three options was
chosen: (1) I have never been prescribed a preventer
inhaler (n=1); (2) I have been prescribed an inhaler but
do not really use it (n=6); or (3) I have a preventer and
usually use it as prescribed (n=10). The mean number
of logins was 1.8 (range 0–7), median 1, (IQR 1–2), and
the average time spent on the website during the study
period was 18 min (range 0–48.9). More detail is shown
in online supplementary ﬁgure A.
Beyond the core ‘introduction’ and ‘my asthma’ sec-
tions, the most popular sections were ‘take the 4-week
challenge’ (n=13), and ‘common concerns and queries’
(n=11). Further usage data are shown in online supple-
mentary table B. The majority (95%) of participants
acknowledged that asthma was impacting on their life
(online supplementary table C).
ACQ score
Our planned analysis was for the seven-question version
of the ACQ, which includes spirometry, for which there
was considerable missing data (n=23; table 1). There was
no signiﬁcant difference in the intervention group com-
pared with the control group (−0.42 (95% CI −0.95 to
0.11), p=0.121). We also analysed the equally valid six-
question version (without spirometry)24 which was
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available for all (n=45), and demonstrated a similar
result and it is this result which is presented in table 2.
Fifty-ﬁve per cent of the intervention group and 48%
of the comparison group achieved the MCID of an
improvement of at least 0.5 points (p=0.767).
AQLQ score
There was no signiﬁcant difference in mini-AQLQ
scores in the intervention group compared with the
control group (table 2). Fifty per cent of the interven-
tion group and 36% in the comparison group achieved
the MCID of improvement of at least 0.5 points
(p=0.379).
Secondary outcomes
The rationale for including a range of secondary out-
comes was to assess their feasibility for inclusion in any
future full-scale RCT. All outcomes were acceptable to
participants and feasible to measure and analyse, apart
from spirometry.
Mini-AQLQ domain scores
The ‘activity limitation’ domain of the mini-AQLQ
showed a statistically signiﬁcant improvement in scores
in favour of the intervention group (table 3). The
remaining individual domains of the mini-AQLQ
showed numerical improvement in the intervention
group, which were not statistically signiﬁcant.
Other patient-centred outcomes
There was a signiﬁcant improvement in PAM scores
(tables 3 and 4) in the intervention group compared
with the control group, indicating that intervention
patients were more highly activated in relation to man-
aging their own health.
There was no signiﬁcant difference in mean MMAS
scores in the intervention group (table 3) compared
with the control group. However, more participants in
the intervention group achieved the MCID≥2 compared
with usual care (30% vs 4%, p=0.034), although the
intervention group did have lower baseline scores.
The change in EQ-5D health utility score showed no
signiﬁcant between-group difference (table 4), with
median change in score of 0 in both groups.
Physiological and inflammatory outcomes
Spirometry analysis included only those meeting ATS
acceptability standards (22/45, 11 per group).22 Effect
sizes were small, and none achieved statistical signiﬁ-
cance (table 3).
Table 1 Baseline demographic characteristics of study population per group
Overall (n=51)
Comparison
(n=26)
Intervention
(n=25)
Age (years), mean (SD) 45.5 (15) 46.4 (14) 44.6 (17)
Female, n (%) 38 (75) 20 (77) 18 (72)
Ethnicity
White, n (%) 48 (94) 24 (92) 24 (96)
Other, n (%) 3 (6) 2 (8) 1 (4)
Smoking status:
Current, n (%) 5 (10) 2 (8) 3 (12)
Former smoker, n (%) 18 (35) 11 (42) 7 (28)
Never smoked, n (%) 28 (55) 13 (50) 15 (60)
SIMD quintile (1=most deprived, 5=least deprived)
SIMD 1, n (%) 14 (28) 7 (27) 7 (28)
SIMD 2, n (%) 11 (22) 6 (23) 5 (20)
SIMD 3, n (%) 9 (18) 4 (15) 5 (20)
SIMD 4, n (%) 5 (10) 3 (12) 2 (8)
SIMD 5, n (%) 12 (24) 6 (23) 6 (24)
Employment status
Employed, n (%) 25 (49) 11 (42) 14 (56)
Unemployed, n (%) 8 (16) 3 (12) 5 (20)
Retired, n (%) 9 (18) 5 (19) 4 (16)
Student, n (%) 2 (4) 1 (4) 1 (5)
Other, n (%) 7 (14) 6 (23) 1 (4)
Education level
Secondary education, n (%) 18 (35) 7 (27) 11 (44)
Tertiary/further education, n (%) 33 (65) 19 (73) 14 (56)
BMI (kg/m2), mean(SD) 30.4 (6.8) 31.3 (8.0) 29.4 (5.2)
Number of comorbidities (over and above index
condition), mean (SD)
2.6 (1.7) 2.6 (1.9) 2.6 (1.4)
Length of asthma diagnosis (years), median (IQR) 18.5 (8.6–28.6) 17.0 (8.6–27.8) 20.3 (9.7–28.6)
BMI, body mass index; SIMD, Scottish Index of Multiple Deprivation.
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Figure 1 Flow of participants
through study. *Actual search
terms refined iteratively through
recruitment (see online
supplementary data file for detail).
ACQ, Asthma Control
Questionnaire score; FeNO,
fractional exhaled nitric oxide;
NHS, National Health Service.
Table 2 Primary outcomes (ACQ and mini-AQLQ)
Intervention Control
Estimated
difference (95% CI) p Value
ACQ score 6-question version (continuous 0–6; 0=totally controlled, 6=severely uncontrolled)
Baseline Mean (SD) 1.87 (0.59) 1.97 (0.68)
Follow-up Mean (SD) 1.22 (0.91) 1.65 (1.15)
Change Mean (SD) −0.65 (1.08) −0.32 (0.94) −0.36 (−0.96 to 0.23) 0.225
ACQ score 6-question version (MCID improvement at follow-up)
Improvement ≥0.5 n (%) 11 (55%) 12 (48%) 0.767
Mini-AQLQ score (continuous 1–7; 1=severely impaired; 7=not impaired at all)
Baseline Mean (SD) 4.97 (1.03) 4.65 (1.02)
Follow-up Mean (SD) 5.40 (1.01) 4.76 (1.30)
Change Mean (SD) 0.43 (0.78) 0.11 (0.88) 0.38 (−0.13 to 0.89) 0.136
Mini-AQLQ score (MCID improvement at follow-up)
Improvement ≥0.5 n (%) 10 (50%) 9 (36%) 0.379
Summaries of scores at baseline, follow-up and change from baseline, with estimated between-group difference from baseline-adjusted linear
regression model with 95% CI and p value. Summaries of achievement of an improvement by more than the MCID at follow-up, with Fisher’s
exact test p values to compare groups.
ACQ, Asthma Control Questionnaire (fall in score is desirable); AQLQ, Asthma Quality of Life Questionnaire (rise in score desirable); MCID,
minimum clinically important difference.
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FeNO levels (indicating airways eosinophilic inﬂamma-
tion) showed no signiﬁcant between-group difference
(table 4).
Medication changes and health service contacts
The median weekly number of puffs of reliever inhaler
used in the intervention group reduced from 11 to 5, but
remained unchanged in the control group at 4 puffs per
week at baseline and at follow-up (p=0.022) (table 4).
Although this between-group change in bronchodilator
use was statistically signiﬁcant, the groups were
imbalanced at baseline. There was no signiﬁcant
between-group difference in the percentage of recom-
mended ICS doses self-reportedly taken, nor the equiva-
lent beclometasone doses prescribed. There were no
signiﬁcant between-group differences in health service
contacts or prednisolone courses prescribed.
Further feasibility outcomes
The PETS results are shown in online supplementary
table A, illustrating barriers to using the website. The
biggest barriers relate to time and opportunity, rather
than content.
No serious adverse events were recorded.
Table 3 Secondary outcomes (continuous variables normally distributed)
Intervention Control
Estimated
difference (95% CI) p Value
Mini-AQLQ symptom domain score (continuous, 1=severely impaired; 7=not impaired at all)
Baseline Mean (SD) 4.56 (1.10) 4.30 (0.84)
Follow-up Mean (SD) 5.15 (1.20) 4.38 (1.35)
Change Mean (SD) 0.59 (1.10) 0.08 (1.05) 0.56 (−0.08 to 1.22) 0.084
Mini-AQLQ activity limitation domain score (continuous, 1=severely impaired; 7=not impaired at all)
Baseline Mean (SD) 5.30 (1.24) 5.31 (1.33)
Follow-up Mean (SD) 5.98 (0.92) 5.38 (1.33)
Change Mean (SD) 0.68 (1.01) 0.07 (1.10) 0.60 (0.05 to 1.15) 0.034
Mini-AQLQ emotional function domain score (continuous, 1=severely impaired; 7=not impaired at all)
Baseline Mean (SD) 5.48 (1.09) 4.80 (1.48)
Follow-up Mean (SD) 5.75 (1.01) 4.84 (1.82)
Change Mean (SD) 0.27 (0.78) 0.04 (1.30) 0.35 (−0.33 to 1.03) 0.301
mini-AQLQ environmental domain score (continuous, 1=severely impaired; 7=not impaired at all)
Baseline Mean (SD) 4.75 (1.39) 4.11 (1.54)
Follow-up Mean (SD) 4.85 (1.30) 4.23 (1.67)
Change Mean (SD) 0.10 (0.89) 0.12 (0.90) 0.08 (−0.46 to 0.62) 0.768
PAM (continuous, 0=no activation; 100=high activation)
Baseline Mean (SD) 65.7 (10.0) 66.2 (14.1)
Follow-up Mean (SD) 73.0 (13.9) 65.7 (16.5)
Change Mean (SD) 7.3 (11.3) −0.5 (12.5) 7.72 (0.53 to 14.90) 0.036
MMAS (continuous, range 0–8, 0=low adherence; 8=high adherence)
Baseline Mean (SD) 4.88 (1.97) 5.59 (1.85)
Follow-up Mean (SD) 5.46 (1.80) 5.82 (1.85)
Change Mean (SD) 0.58 (1.37) 0.23 (1.03) 0.19 (−0.50 to 0.88) 0.586
MMAS (MCID improvement at follow-up)
Improvement ≥2.0 n (%) 6 (30) 1 (4) 0.034
FEV1 (L) (continuous) (n=22)
Baseline Mean (SD) 2.62 (0.56) 2.66 (0.69)
Follow-up Mean (SD) 2.72 (0.58) 2.68 (0.49)
Change Mean (SD) 0.10 (0.18) 0.02 (0.31) 0.08 (−0.12 to 0.27) 0.428
FEV1% predicted (continuous) (n=22)
Baseline Mean (SD) 87.4 (13.6) 85.2 (17.1)
Follow-up Mean (SD) 90.6 (13.8) 85.7 (11.8)
Change Mean (SD) 3.3 (6.3) 0.6 (9.4) 3.4 (−2.8 to 9.5) 0.265
FEV1/FVC (%) (continuous) (n=22)
Baseline Mean (SD) 76.7 (7.0) 77.6 (10.9)
Follow-up Mean (SD) 79.1 (6.7) 80.2 (9.5)
Change Mean (SD) 2.4 (5.3) 2.6 (4.5) −0.4 (−3.9 to 3.1) 0.829
Summaries of scores at baseline, follow-up and change from baseline, with estimated between-group difference from baseline-adjusted linear
regression model with 95% CI and p value. Summaries of achievement of an improvement by more than the MCID at follow-up, with Fisher’s
exact test p values to compare groups. N=45 unless otherwise stated.
p Values in bold indicate significance <0.05.
ACQ, Asthma Control Questionnaire; AQLQ, Asthma Quality of Life Questionnaire; FEV1, forced expiratory volume in 1 s; FVC, forced vital
capacity; MCID, minimum clinically important difference; MMAS, Morisky Medication Adherence Score; PAM, Patient Activation Measure.
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The main source of missing data was from the spirom-
etry results where 23 participants had results not suitable
for analysis, due to not meeting ATS criteria. All ques-
tionnaires were completed sufﬁciently well to allow cal-
culation of scores, with only one response missing from
each of the mini-AQLQ, PAM and MMAS all from differ-
ent participants.
Sample size for a fully powered subsequent study
Using baseline-adjusted calculations of the change in
ACQ score above assuming a SD of 1.0, a sample size of
134 would be required to detect a between-group
change of ≥0.5 (MCID) in ACQ with 90% power at 0.05
signiﬁcance. Assuming a similar attrition rate of 12%,
the total sample size required would be 154.
DISCUSSION
Principal findings
This phase 2 pilot RCT of the Living well with Asthma
resource demonstrates that this website merits further
development, and that subsequent progression to a full-
scale phase 3 RCT is feasible. Recruitment targets were
achieved, and attrition rates were comparable to rates of
other published digital interventions.9 We had no upper
age limit, unlike similar asthma digital intervention
studies. This is important as our recent metareview only
found one study that included participants over 50 years
of age, and descriptions of participants’ characteristics
were limited, with socioeconomic status ignored.9 This
information is important to understand the ‘reach’ of
the intervention.
In terms of primary efﬁcacy outcomes, there were no
signiﬁcant between-group differences in terms of ACQ
and mini-AQLQ, although it is important to note that
this pilot trial was not powered to show such differences.
However, there are some interesting ﬁndings in analysis,
as both the ACQ and mini-AQLQ demonstrate encour-
aging and consistent trends in favour of the intervention
group, with one subdomain of the AQLQ (activity limita-
tion) reaching the MCID and statistical signiﬁcance. It is
worth noting that for both primary efﬁcacy outcomes, a
proportion of those in the comparison group demon-
strated an improvement in MCID scores as well as the
Table 4 Secondary outcomes (variables not normally distributed)
Intervention Comparison p Value
EQ-5D health utility (continuous, 0.000=dead; 1.000 perfect health)
Baseline Median (IQR) 0.848 (0.725, 1.000) 0.796 (0.620, 1.000)
Follow-up Median (IQR) 1.000 (0.796, 1.000) 0.796 (0.727, 1.000)
Change Median (IQR) 0.000 (0.000, 0.111) 0.0000 (−0.052, 0.194) 0.972
EQ-5D visual analogue scale (continuous, 0 worst health; 100 best health)
Baseline Median (IQR) 75 (70, 84) 80 (70, 90)
Follow-up Median (IQR) 80 (73, 88) 80 (70, 90)
Change Median (IQR) 2.5 (−6.5, 13.0) 1.0 (−10, 10) 0.409
FeNO (continuous, low score indicates low inflammation)
Baseline Median (IQR) 26.0 (16.0, 46.5) 25.0 (11.0, 36.0)
Follow-up Median (IQR) 23.0 (12.0, 44.5) 19.0 (10.0, 27.0)
Change Median (IQR) −2.5 (−11.5, 8.5) −2.0 (−15.0, 2.0) 0.615
Puffs reliever taken per average week(continuous)
Baseline Median (IQR) 11 (7, 28) 4 (2, 12)
Follow-up Median (IQR) 5 (0.5, 14) 4 (0, 28)
Change Median (IQR) −7 (−14, 1) 0 (−4, 4) 0.022
Percentage prescribed ICS reportedly taken (continuous)
Baseline Median (IQR) 85.7 (14.3, 100.0) 100.0 (71.4, 100.0)
Follow-up Median (IQR) 92.9 (71.4, 100.0) 100.0 (85.7, 100.0)
Change Median (IQR) 0.0 (0.0, 14.3) 0.0 (0.0, 7.1) 0.730
Equivalent beclometasone dose (μg) (continuous)
Baseline Median (IQR) 400 (300, 1000) 800 (400, 800)
Follow-up Median (IQR) 400 (300, 1000) 800 (400, 800)
Change Median (IQR) 0 (0, 0) 0 (0, 0) 0.209
Prednisolone course n (%) with at least one 1 (5) 3 (12) 0.617
Hospital/A&E visit n (%) with at least one 0 0 –
Non-routine GP/nurse visit n (%) with at least one 3 (15) 6 (24) 0.710
Routine GP/nurse visit (eg, asthma
review)
n (%) with at least one 5 (25) 8 (32) 0.745
Summaries of scores at baseline, follow-up and change from baseline. Summaries of prescribing and health service use over the study
period, with Fisher’s exact test for categorical data, and Mann-Whitney test to compare median differences between groups.
p Values in bold indicate significance <0.05.
A&E, accident and emergency; ACQ, Asthma Control Questionnaire; AQLQ, Asthma Quality of Life Questionnaire; EQ-5D, EuroQol; FeNO,
fractional exhaled nitric oxide; GP, general practitioner; ICS, inhaled corticosteroids.
Morrison D, et al. BMJ Open 2016;6:e009254. doi:10.1136/bmjopen-2015-009254 7
Open Access
group.bmj.com on June 13, 2016 - Published by http://bmjopen.bmj.com/Downloaded from 
intervention group. This is often the case in unblinded
complex intervention trials, and validates our approach
of making this a pilot RCT, and not just a feasibility
study. In terms of website use, 76% of individuals
logging in is comparable with other behaviour change
websites,25 26 and it is encouraging that an average of
only 18 min usage resulted in consistently positive trends
across almost all outcomes. Asthma-speciﬁc research
indicates that users like to spend 5–8 min per online
session.27 Our exploration of usage patterns suggests
that some users missed sections that they could poten-
tially have beneﬁted from. These two facts combined
lead us to conclude that it would be preferable to
provide the core modules initially and then ‘release’
further sections weekly or fortnightly, a strategy that has
been used successfully for a weight loss intervention also
developed using LifeGuide software.26 Qualitative
process evaluation interviews of those in the intervention
group have been completed and will be reported separ-
ately. Findings from this qualitative work will inform the
further development of this resource, prior to evaluation
in a full-scale trial.
We assessed the feasibility of collecting a range of sec-
ondary outcomes in any future RCT, and in doing so
demonstrated a signiﬁcant improvement in the PAM,
which indicates that those in the intervention group had
improved knowledge, conﬁdence and skills to manage
their asthma. Signiﬁcant between-group differences in
the numbers of patients showing a MCID improvement
in adherence and reliever use should be interpreted
with caution due to baseline between-group imbalances.
The feasibility of researchers undertaking spirometry in
the participants’ own homes using a portable handheld
device was found to be low, as reported in other
studies.28 Potential solutions include more intensive
training of research staff; use of a device providing
test-by-test acceptability information or undertaking trial
visits in a dedicated clinical research facility by staff
experienced in spirometry. However, this latter solution
could have a negative effect on recruitment, as 21% of
our study visits were undertaken in the evening and
weekend, which facilitated recruitment of a population
who can rarely make it into such RCTs (full-time
employed). There is a balance between precision of
measurements versus encouraging a more representative
sample. Whether spirometry is required at all in a study
aimed at people with mild-to-moderate asthma is not
clear, and there is precedence in the literature for not
including these outcome measures in similar primary
care-based trials or for using simpler to perform lung
function measures such as peak expiratory ﬂow rate.29 30
Lack of time and opportunity were the biggest bar-
riers to using the website and providing the contents
on a smartphone app or tablet would be worth investi-
gating. During the introduction questions at the start of
the website, 95% of users agreed to statements which
showed that asthma was negatively impacting on their
lives. However, at the end of the trial, 42% of users
doubted the personal relevance of the website, anec-
dotally reporting that the website would be more useful
for people with symptomatic asthma. To be in the trial
in the ﬁrst place, all users were symptomatic (as
deﬁned by ACQ score), so challenging this mismatch
between users’ perceptions and the reality would be
warranted in future versions of a mobile friendly digital
intervention.
Strengths and limitations
Blinding to group allocation during analysis was not pos-
sible due to the different numbers in each group being
known by the researcher undertaking the analysis. As
with many digital interventions, the ‘reach’ is a potential
issue and our low response rate is a concern, even
taking into account our very broad recruitment strategy.
Similar trials have described similar recruitment difﬁcul-
ties.31 However, given how common asthma is, improve-
ments in even a small proportion of patients could lead
to signiﬁcant beneﬁt overall, particularly with an inter-
vention such as that trialled here which is entirely inter-
net based and once developed is very economical to
make available to large numbers of people. Therefore,
what seems like a low reach can still improve outcomes
for a large number of people. We have described our
population in detail, and our baseline characteristics
demonstrate that patients were recruited from a range
of socioeconomic backgrounds. Those excluded due to
not having internet access were older than those who
were excluded for other reasons (data not shown), but
this is becoming less of an issue with year-on-year
increases in the number of households with internet
access (84% in 2014, UK).32
Comparable studies in the literature
Our recently published metareview suggests digital inter-
active interventions to support asthma self-management
show promise, but there is no clear picture about the
‘active ingredients’ of the interventions.9 In the develop-
ment of this intervention, we have described its contents
fully including an analysis of behaviour change techni-
ques used,13 allowing more meaningful future compari-
sons. When focusing on interventions aimed at those
with mild-to-moderate asthma, most have included con-
siderable health professional input as well as self-
monitoring work on the part of the participants, and
have not shown clinical improvements.33 This evaluation
of Living Well with Asthma adds to the literature on
digital asthma self-management suggesting that an inter-
vention not including regular user self-monitoring or
costly health professional input may have positive
results.
Future research
We have shown that evaluating the Living Well with
Asthma intervention was feasible and resulted in encour-
aging trends in clinical outcomes. Further qualitative
work to understand usage patterns with intervention
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group participants have been completed and will inform
a future version of the resource. To overcome the ‘prac-
tical barriers’ to using the intervention, future versions
need to be mobile and tablet compatible, and will
require further user testing. Following this development
work on the resource, these ﬁndings suggest that a
large-scale phase 3 RCT is merited, with some explor-
ation of recruitment strategies and minor modiﬁcation
to outcome measurement methods. Low-intensity digital
interventions that are easier to deliver at scale may be a
more successful strategy, particularly in those with
mild-to-moderate asthma.
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